摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-Amino-4-methylpentan-2-ol | 1333608-52-8

中文名称
——
中文别名
——
英文名称
5-Amino-4-methylpentan-2-ol
英文别名
——
5-Amino-4-methylpentan-2-ol化学式
CAS
1333608-52-8
化学式
C6H15NO
mdl
MFCD19982516
分子量
117.191
InChiKey
BSJILSAQCDSDCN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    182.7±23.0 °C(Predicted)
  • 密度:
    0.904±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    8
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    46.2
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    二异丁基氢化铝 作用下, 以 四氢呋喃 为溶剂, 反应 12.0h, 生成 5-Amino-4-methylpentan-2-ol
    参考文献:
    名称:
    Predictable Stereoselective and Chemoselective Hydroxylations and Epoxidations with P450 3A4
    摘要:
    Enantioselective hydroxylation of one specific methylene in the presence of many similar groups is debatably the most challenging chemical transformation. Although chemists have recently made progress toward the hydroxylation of inactivated C-H bonds, enzymes such as P450s (CYPs) remain unsurpassed in specificity and scope. The substrate promiscuity of many P450s is desirable for synthetic applications; however, the inability to predict the products of these enzymatic reactions is impeding advancement. We demonstrate here the utility of a chemical auxiliary to control the selectivity of CYP3A4 reactions. When linked to substrates, inexpensive, achiral theobromine directs the reaction to produce hydroxylation or epoxidation at the fourth carbon from the auxiliary with pro-R facial selectivity. This strategy provides a versatile yet controllable system for regio-, chemo-, and stereoselective oxidations at inactivated C-H bonds and demonstrates the utility of chemical auxiliaries to mediate the activity of highly promiscuous enzymes.
    DOI:
    10.1021/ja200551y
点击查看最新优质反应信息

文献信息

  • NEW COMPOUNDS
    申请人:Hauel Norbert
    公开号:US20110098282A1
    公开(公告)日:2011-04-28
    Novel compounds of which the following is exemplary:
    新颖的化合物,以下是其中的一个例子:
  • COMPOUNDS
    申请人:Hauel Norbert
    公开号:US20110077231A1
    公开(公告)日:2011-03-31
    Novel compounds, with the following being exemplary:
    新化合物,以下是一些示例:
  • NOVEL COMPOUNDS
    申请人:Hauel Norbert
    公开号:US20110294775A1
    公开(公告)日:2011-12-01
    Novel compounds which are useful for treating acute pain, visceral pain, neuropathic pain, inflammatory/pain receptor-mediated pain, tumour pain and headache diseases. The following is exemplary:
    新颖的化合物,可用于治疗急性疼痛、内脏疼痛、神经痛、炎症/疼痛受体介导的疼痛、肿瘤疼痛和头痛疾病。以下是示例:
  • [EN] PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T<br/>[FR] MODULATEURS QUINOLINYLES À LIAISON PHÉNYLE DE RAR-GAMMA-T
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2015057203A1
    公开(公告)日:2015-04-23
    The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    本发明涵盖了Formula I的化合物。其中Formula I中:R1、R2、R3、R4、R5、R6、R7、R8和R9在说明书中有定义。该发明还涵盖了一种治疗或改善综合征、疾病或疾病的方法,其中所述综合征、疾病或疾病是类风湿性关节炎或牛皮癣。该发明还涵盖了通过给予权利要求1中至少一种化合物的治疗有效量来调节哺乳动物中的RORγt活性的方法。
  • PHENYL LINKED QUINOLINYL MODULATORS OF RORyt
    申请人:Janssen Pharmaceutica NV
    公开号:US20150105404A1
    公开(公告)日:2015-04-16
    The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    本发明包括以下式I的化合物:其中:R1、R2、R3、R4、R5、R6、R7、R8和R9在说明书中定义。该发明还包括一种治疗或改善综合症、疾病或疾病的方法,其中所述综合症、疾病或疾病为类风湿性关节炎或牛皮癣。该发明还包括通过给予至少一种权利要求1的化合物的治疗有效量来调节哺乳动物中RORγt活性的方法。
查看更多